RNA Atrium Therapeutics
Atrium Therapeutics earnings company data as of 4:48 AM ET 10/23
History
2 periods, newest first. Each row shows EPS above revenue.
| Period | Date | Metric | Estimate | Actual | Result |
|---|---|---|---|---|---|
| FY2026 Q3 | 12 Nov | EPS | — | — | — |
| Rev | — | — | — | ||
| FY2026 Q2 | 13 Aug | EPS | — | -1.18 | — |
| Rev | — | $3.0M | — |
Insider trades
Open-market buys and sales by RNA's executives, directors and 10% owners in the last 12 months, from their Form 4s
- None no insider bought on the open market
- None no sales outside a trading plan
- None no planned (10b5-1) sales
No open-market buys or sales on file.
Also filed in the last 12 months, not counted as buying or selling: 8 share withholdings for taxes and 6 stock grants.
SEC filings
Recent issuer filings from EDGAR, 16 shown.
| Filed | Form | Detail | Links |
|---|---|---|---|
| 8-K/A | 8.01 | Filing Doc | |
| 8-K | 1.01,3.02,8.01,9.01 | Filing Doc | |
| SCHEDULE 13G/A | — | Filing Doc | |
| SCHEDULE 13G | — | Filing Doc | |
| SCHEDULE 13G/A | — | Filing Doc | |
| 8-K | 2.02,9.01 | Filing Doc | |
| 10-Q | Filing Doc | ||
| SCHEDULE 13G/A | — | Filing Doc | |
| 8-K | 8.01,9.01 | Filing Doc | |
| SCHEDULE 13G | — | Filing Doc | |
| 8-K | 2.02,9.01 | Filing Doc | |
| 10-Q | Filing Doc | ||
| SCHEDULE 13G | — | Filing Doc | |
| SCHEDULE 13G | — | Filing Doc | |
| 8-K | 1.01,5.01,5.02,9.01 | Filing Doc | |
| 8-K | 7.01,9.01 | Filing Doc |
No filings match this filter.
Estimates are consensus figures; SEC filings remain the official record. Not investment advice.